Teronac

Quick links to important sections

Teronac

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Teronac

Teronac: Quick Facts

Property Description
Active ingredient Mazindol
Form Tablet
Pharmacological class Centrally Acting Antiobesity Product
General purpose Appetite suppression
Origin Synthetic organic compound

What Type of Medicine is Teronac (Mazindol)?

Teronac is a prescription-only pharmaceutical product whose core active ingredient is Mazindol, a synthetic compound belonging to the Centrally Acting Antiobesity Product class. Mazindol is categorized as an anorexigenic agent (appetite suppressant), a therapeutic classification defined by its primary function of modulating food intake. Chemically, Mazindol has a distinctive tricyclic structure that is unrelated to the chemical structure of traditional amphetamine-based stimulants. Mazindol's unique chemical profile allows it to act on appetite control pathways in the brain, a distinction compared to older anorectic agents.

Teronac: Composition and Physical Form

The composition of Teronac is based on Mazindol as the sole active substance, qualifying it as a single-ingredient product. Mazindol is a synthetic organic compound with the molecular formula C16H13ClN2O. The medication is designed for oral administration and is supplied in a solid tablet form, making it a convenient option for administration. The INN, Mazindol, has also been available under other trade names such as Sanorex and Mazanor in various global markets, though Teronac remains a distinct, single-entity brand.

What is the General Purpose of Teronac?

The general purpose of Teronac is to provide appetite suppression as an adjunct to a comprehensive weight-reduction regimen, typically used for patients facing exogenous obesity. It functions as a monoamine reuptake inhibitor, thereby increasing the concentration of key neurotransmitters, including norepinephrine, dopamine, and serotonin. This neurochemical action influences the hypothalamus by stimulating the satiety center and inhibiting the feeding center. This neurochemical action is associated with decreased caloric intake, which ultimately supports the short-term management of excess body weight.

What side effects are possible with Teronac?

Possible Side Effects and Safety Information

The official safety profile for Teronac (Mazindol) is defined by officially documented adverse reactions that primarily affect the Central Nervous System and Cardiovascular Systems. Safety information is organized into categories consistent with regulatory documents, detailing both common and serious possible effects.

Documented Adverse Reactions

The most frequent adverse reactions listed in regulatory information involve the Gastrointestinal and Nervous Systems. Common effects may include dry mouth, insomnia, headache, dizziness, nervousness, tremor, and gastrointestinal disturbances such as constipation or diarrhea.

Serious Safety Considerations

Official labeling documents certain serious, rare reactions and specific long-term risks. These serious adverse reactions include Pulmonary Hypertension and Cardiac Valve Dysfunction (valvulopathy), as well as Severe Hypertension and Seizures. Furthermore, due to the drug's properties, there is an established risk of developing Psychological Dependence and Abuse.

Safety Restrictions and Limitations

Official prescribing information mandates strict limitations on use. The medicine is contraindicated in patients with specific pre-existing conditions, including a history of cardiovascular disease (such as coronary artery disease or cardiac arrhythmias), glaucoma, hyperthyroidism, severe hepatic or renal insufficiency, and a history of drug or alcohol abuse. Use is also restricted with Monoamine Oxidase Inhibitors (MAOIs).

Time-related safety patterns are also noted, including the potential for tolerance to the appetite-suppressing effect to develop over a few weeks, and the risk of withdrawal effects if the medication is stopped abruptly after continuous use.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Teronac (Mazindol) overdose strictly defines the expected clinical presentations and the mandated emergency response actions, based on authoritative government documentation.

Documented overdose manifestations affect the Central Nervous System, Cardiovascular System, and Gastrointestinal System. CNS and systemic signs include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, and aggressiveness. Gastrointestinal manifestations, such as nausea, vomiting, and diarrhea, are also listed in the official prescribing information.

Overdose is associated with severe and potentially life-threatening outcomes, specifically irregular heartbeat (cardiac arrhythmias) and seizures. Due to the risk of these critical manifestations, the official regulatory documentation explicitly mandates that the user seek emergency medical attention immediately upon any suspicion of overdose.

Management of the overdose is restricted to symptomatic and supportive treatment, aimed at stabilizing the patient and controlling the documented clinical signs. The official label also confirms that no specific antidote for Mazindol overdose is known. This supportive approach and the requirement for immediate professional care constitute the entire regulatory protocol for overdose situations.

Therapeutic Uses of Teronac

What Teronac Treats: Main Uses and Benefits

Teronac (Mazindol) is a prescription medication used to provide short-term, adjunctive support in the comprehensive management of exogenous obesity. Its therapeutic application is considered when pharmacological support may be considered relevant when diet and exercise alone have proven insufficient to support the goal of meaningful weight reduction.


Key Therapeutic Focus

The medication is commonly used to help manage conditions characterized by periods of heightened symptoms such as moderate to severe obesity (BMI greater than or equal to 30 kg/m²) or in high-risk patients with lower BMI (BMI > 27 kg/m²). The primary therapeutic indication is for exogenous obesity, alongside its supportive role in managing the pathological appetite that presents as symptoms related to systemic imbalance and high caloric drive.

A primary benefit is that it may assist with the goal of body weight reduction over the short term. When applied in clinical settings that involve acute or unstable symptom patterns, the medicine supports the patient during difficult episodes by easing the distressing symptoms of hunger, which contributes to easing the overall symptom burden.

“The therapy is used to offer supportive relief by addressing symptoms related to heightened physiological activity such as persistent, excessive appetite.”

Quick Fact: Relief for Pathological Appetite
Primary Symptom Domain: Persistent, overwhelming hunger (symptoms that interfere with daily functioning).
Clinical Context: Adjunct therapy relevant when supportive symptom management is appropriate.
Patient Benefit: Supports adherence to necessary dietary restriction.

Eligibility and Restrictions for Use

Who Can and Cannot Use Teronac (Mazindol)?

Eligibility for Teronac is strictly defined by regulatory authorities and centers on age, underlying health conditions, and current physiological status.


Approved Populations and Age Restrictions

Teronac is intended for short-term, adjunctive use in adults and adolescents aged 12 years and older who meet specific criteria for exogenous obesity, typically based on high Body Mass Index (BMI). Use in children under 12 years of age is contraindicated.


Absolute Contraindications

The medicine is contraindicated (must not be used) in several patient groups, including:

  • Cardiovascular Disease: Patients with a history of coronary artery disease, stroke, cardiac arrhythmias, or severe/unstable hypertension.
  • Psychiatric and Substance Use: Individuals with a history of drug/alcohol abuse or specific psychiatric conditions like anorexia nervosa.
  • Organ Function: Patients with severe renal insufficiency or severe hepatic insufficiency.
  • Glaucoma: Patients with narrow-angle glaucoma.
  • Concomitant Use: Patients who have taken a Monoamine Oxidase Inhibitor (MAOI) in the preceding 14 days.

Pregnancy and Lactation

Use of Teronac is contraindicated during both pregnancy and lactation (breastfeeding).

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Teronac (Mazindol) is defined by pharmacodynamic constraints, requiring strict adherence to regulatory restrictions, primarily focused on its effects on monoaminergic and cardiovascular systems.

Interaction Category Specific Restriction or Outcome
Contraindicated Combinations Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is prohibited due to the risk of a severe hypertensive crisis. The drug is also contraindicated with other centrally acting anorectic agents due to the potential for pulmonary artery hypertension.
Timing-Separation Rules A period of at least 14 days must elapse after discontinuing an MAOI before beginning Mazindol therapy.
Serotonergic/Sympathomimetic Agents Co-administration with Serotonergic Agents (such as SSRIs) may increase the risk of Serotonin Syndrome. Combining with other Sympathomimetic Agents can lead to additive increases in blood pressure and heart rate.
Metabolic/Glucose Management Mazindol may reduce the efficacy of antihypertensive agents. Dosage adjustments for Insulin and oral hypoglycemic agents may be required due to the drug’s potential to affect blood glucose levels.
Non-Medicinal Substances Consumption of Alcohol (ethanol) must be avoided as it may potentiate the central nervous system and cardiovascular effects. The herbal product St. John's Wort is cautioned against due to the risk of Serotonin Syndrome.

This interaction structure dictates that specific drug classes and non-medicinal substances must be managed with caution or prohibition due to additive effects and the risk of severe adverse events.

Mechanism of Action

How Teronac Works: Mechanism of Action

Teronac employs a dual mechanism of action to modulate signaling within the central nervous system (CNS). This action targets both monoamine reuptake transporters and a key neuropeptide receptor system.


Modulation of Monoamine Pathways

Teronac functions as a triple monoamine reuptake inhibitor. It primarily acts by blocking the reuptake of specific monoamine neurotransmitters, including norepinephrine, dopamine, and, to a lesser extent, serotonin, at the presynaptic terminals. This action prolongs the concentration and duration of these signaling molecules in the synaptic cleft, thereby influencing activity in neural circuits associated with energy balance and arousal.


Direct Orexin System Engagement

A distinct component involves Teronac acting as an agonist at the orexin-2 receptor ( OX2R). The orexin system is a neuropeptide pathway critical for regulating wakefulness. Activating this receptor initiates specific downstream signaling sequences that modulate activity within the neural circuits governing energy balance and arousal.


Integrated Mechanistic Influence

The combination of triple monoamine reuptake inhibition and OX2R agonism influences two distinct, yet interacting, central regulatory systems. This combined influence modifies the signaling dynamics within the central pathways involved in physiological regulation, resulting in altered mechanistic activity patterns across CNS pathways.

Dosage and Administration Information

How to Use Teronac

Teronac (Mazindol) is administered exclusively by the oral route as a tablet and is intended for short-term use only, typically as part of a structured program that includes caloric restriction and exercise. Administration patterns align with its designated use as an adjunctive treatment.


Official Dosing and Administration Schedule

Instruction Detail
Route of Administration Oral administration only.
Dosing Schedule Therapy typically initiates with 0.5 mg to 1 mg daily. The dose may be advanced to a maintenance range of 1.5 mg to 2 mg daily, not to exceed the established maximum total dose of 3 mg per day.
Frequency and Timing Generally administered once daily, preferably in the morning. The daily dose may be divided, but evening administration is strictly discouraged to help prevent insomnia.
Duration of Treatment The course of therapy is defined as short-term, typically limited to 4 to 6 weeks, with a maximum duration generally not exceeding 12 weeks in accordance with prescribing guidelines.

Administration Conditions

To ensure proper intake, the tablet should be taken with a full glass of water. While it is generally administered before meals, the medicine may be taken with food if necessary to minimize the potential for gastric discomfort. This medication is not approved for use in children under 12 years of age, while use in adolescents over 12 is based on the same general adult dosing principles.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Teronac (Mazindol)

Evidence from Short-Term Clinical Trials for Exogenous Obesity

Teronac, containing the active ingredient Mazindol, was evaluated in research exploring its adjunctive role in the short-term context of exogenous obesity, which is a condition marked by functional limitations related to excess body weight. The main evidence base consists of older randomized controlled trials (RCTs) and subsequent systematic reviews that consolidate findings from these primary studies. The patients studied in these research scenarios were typically adults with obesity (BMI ge 30 kg/m^2) or those classified as overweight with certain co-morbidities (BMI ge 27 kg/m^2).

These studies focused on research exploring short-term symptom changes, primarily by studies monitored outcomes related to systemic imbalance and outcomes describing episodic or acute changes in appetite. Systematic reviews reported that, when compared to a placebo, findings describe patterns observed in the studies such as observed short-term weight change measurements over the short-term treatment period, often defined as less than 180 days. These research highlights changes measured during the study period but are generally limited to the initial few months of use.

Analyzing Outcomes Measured in Clinical Research

The research primarily monitored high-level endpoints such as absolute body weight change (in kilograms) and the percentage of participants who reached a specific goal, such as 5% or 10% weight reduction from baseline. Studies also examined patient-reported outcomes describing perceived discomfort related to persistent hunger or appetite. Additionally, some trials explored changes in outcomes related to systemic or functional imbalance by taking measurements of metabolic parameters, including blood pressure, serum lipids, and indicators of blood sugar control.

Limitations and Research Gaps

Overall, the research base contributes to the broader evidence landscape regarding short-term weight management, but the evidence quality may be variable. Key scientific limitations include that many of the core randomized trials are older and their sample sizes were modest, contributing to a high or unclear risk of bias as reported by systematic reviews. Furthermore, data for certain groups remain insufficient when assessing crucial outcomes like long-term cardiovascular or metabolic changes. The current evidence highlights what is known—and what is still uncertain—with regulators noting the absence of modern, large-scale, long-term RCTs for Mazindol that meet current scientific standards.

Key Studies & References

  1. Drugs Used for Weight Reduction: A Meta-Analysis of Clinical Trials
  2. Mazindol: DrugBank Accession DB00898

Frequently Asked Questions (FAQ)

Common questions about Teronac (FAQ)


Q: How quickly does Teronac start working?

Studies and official information indicate that the appetite-suppressing effects of Teronac often begin relatively quickly. Evidence suggests that, due to the medicine's central nervous system activity, effects may be noted within a few hours following administration.


Q: How long do the effects of Teronac last after taking it?

The effects of Teronac are sustained throughout the day. This is implied by official administration instructions, which advise against taking a dose too late in the evening. The guidance regarding administration timing is provided to address the potential for insomnia.


Q: Can Teronac be taken with food?

Official guidance notes that while Teronac is generally taken before meals, it may be administered with food. The medicine can be taken with food if necessary, as this may minimize the potential for gastric discomfort.


Q: What happens if I miss a dose of Teronac?

Official regulatory information describes taking the missed dose as soon as it is remembered. However, if it is close to the next scheduled dose or already in the evening, the missed dose is typically skipped because taking it too late may cause insomnia.


Q: Can I drink alcohol while taking Teronac?

Regulatory information states that consumption of alcohol (ethanol) must be avoided while using this medicine. This restriction is due to the potential for alcohol to potentiate, or increase, the central nervous system and cardiovascular effects of Teronac.


Q: What are the most common side effects people report online?

The most frequently documented adverse reactions in official labeling involve the gastrointestinal and nervous systems. These common effects include dry mouth, insomnia, headache, dizziness, nervousness, and constipation or diarrhea.


Q: Is it normal to feel tired when you first start taking Teronac?

Tiredness or drowsiness is not explicitly listed among the common adverse reactions documented in official information. Regulatory warnings note that this type of medicine has the potential to mask the symptoms of extreme tiredness.


Q: Does Teronac affect sleep (cause insomnia or drowsiness)?

Insomnia, or difficulty sleeping, is documented as a common adverse reaction associated with the use of Teronac. This effect is why the medication is often recommended to be taken in the morning to limit its impact on nighttime sleep.


Q: Is there a generic version of Teronac available?

Mazindol is the active ingredient in Teronac. While Teronac is a distinct brand, Mazindol has been available under other trade names, such as Sanorex and Mazanor, in various global markets.


Q: Does Teronac interact with supplements like vitamins or herbal remedies?

Regulatory documents specifically caution against co-administration with the herbal product St. John's Wort. This combination carries a risk of Serotonin Syndrome, which is a potentially serious side effect.


Q: What are the official guidelines for stopping Teronac?

Official information notes an established risk of psychological dependence and a potential for withdrawal effects if the medication is stopped suddenly after continuous use. Official guidance notes that discontinuation is typically managed gradually under the direction of a healthcare professional.


Q: Why is Teronac sometimes given for a short period only?

Teronac is designated for short-term use, as official information notes the potential for tolerance to the appetite-suppressing effect to develop over a few weeks. The duration of therapy is typically limited by regulatory guidelines.


Q: What kind of monitoring is needed while taking Teronac?

The medication can affect blood pressure and blood sugar levels. For patients with diabetes, and due to the medicine’s potential effects on blood pressure, official guidelines specify the need for monitoring cardiovascular status and blood glucose control.


Q: Is Teronac a type of antibiotic?

No, Teronac is not an antibiotic. It is classified by regulatory bodies as a Centrally Acting Antiobesity Product, which is an anorexigenic agent (an appetite suppressant).


Q: Can Teronac cause weight gain or loss?

The general purpose of the medicine is appetite suppression as an adjunctive therapy for weight reduction. Unexplained weight gain is not listed as an adverse reaction in the official prescribing information.


Q: Is Teronac considered a high-risk medication?

Teronac is categorized as a Schedule IV controlled substance due to the established risk of dependence and abuse. It is also contraindicated in patients with specific severe pre-existing conditions, including cardiovascular disease, glaucoma, and severe organ insufficiency.


Q: How long do people usually stay on Teronac treatment?

The course of therapy is defined as short-term. Official guidelines typically limit treatment to 4 to 6 weeks, with a maximum duration generally not exceeding 12 weeks.


Q: What does the FDA or EMA say about Teronac?

Regulatory bodies like the FDA and EMA define Teronac as a prescription-only, centrally acting anorexigenic agent. Due to the established risk of dependence, it is classified as a Schedule IV controlled substance in the U.S.


Q: What are the signs of an overdose of Teronac?

Symptoms of an overdose documented in regulatory information may include restlessness, tremor, rapid breathing, confusion, and hallucinations. More severe signs can involve panic, aggressiveness, an irregular heartbeat, and seizures.


Q: Can Teronac worsen any existing health conditions?

Official documentation indicates that the medicine is contraindicated in patients with a history of certain pre-existing conditions, such as cardiovascular disease, severe hypertension, glaucoma, and severe hepatic or renal insufficiency.


Q: Is it okay to crush or chew Teronac tablets?

Teronac is supplied as a tablet for oral administration. Official instructions for this form do not specify that it should be crushed or chewed before swallowing.


Q: Can Teronac cause skin reactions or a rash?

Official labeling for serious adverse effects includes allergic reactions. These allergic reactions may involve external signs, such as swelling or hives.


Q: Can I get Teronac without a prescription (over-the-counter)?

Teronac is defined by regulatory bodies as a prescription-only pharmaceutical product. It cannot be obtained without a prescription.


Q: What are the symptoms of withdrawal when discontinuing Teronac?

Regulatory information notes the potential for withdrawal effects if the medication is stopped abruptly. These documented symptoms may include restlessness, nervousness, and tremor.

How should Teronac be stored and disposed of?

Teronac (Mazindol) is subject to specific regulatory storage and disposal mandates, primarily due to its classification as a Schedule IV controlled substance.

Official Storage Requirements

Condition Requirement
Temperature Store at room temperature (20°C to 25°C).
Container Keep in a tightly closed, original container.
Security Must be stored locked up (P405) to prevent unauthorized access.

Disposal Instructions

Official guidelines require that unused or expired Teronac be disposed of in compliance with federal and local regulations for controlled substances. Disposal must be conducted in a manner that renders the medicine non-retrievable, often utilizing authorized drug take-back programs. It is strictly mandated not to allow the product to enter the sewer system or surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Teronac found in:

A-Z Index: